This brand name is authorized in Japan
The drug BYCLOT contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Coagulation factor X
UNII 0P94UQE6SY - COAGULATION FACTOR X HUMAN
|
|
Coagulation factor X is derived from human plasma and used as a replacement for the naturally existing coagulation factor X in patients with hereditary factor X deficiency. |
|
2
Coagulation factor VIIa
UNII 15FH07392N - COAGULATION FACTOR VIIA HUMAN
|
|
Pharmacological doses of rFVIIa activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor. |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 6343500D1027 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
